Navigation Links
Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
Date:11/5/2013

BASKING RIDGE, N.J., Nov. 5, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Michael E. Mendelsohn, M.D., to the company's Board of Directors.  The appointment strengthens Regado's leadership team by infusing the Company with a world-renowned leader in cardiovascular research and clinical development as the Phase 3 REGULATE-PCI clinical trial is actively enrolling patients worldwide.

Dr. Mendelsohn brings to Regado an unparalleled combination of cardiovascular therapeutic expertise, large pharmaceutical company experience and academic achievement. Since June 2010, Dr. Mendelsohn has served as Senior Vice President and Global Franchise Head for Cardiovascular Diseases at Merck & Co.  While at Merck, he led research and development and global strategy for all cardiovascular programs from Discovery to Late Development. Prior to joining Merck in 2010, Dr. Mendelsohn spent 17 years at Tufts Medical Center, where he served as the first-ever Chief Scientific Officer and the Executive Director of the center's Molecular Cardiology Research Institute. Dr. Mendelsohn received his undergraduate degree in Chemistry and English from Amherst College and his M.D. from Harvard Medical School. He completed his residency in internal medicine and fellowship in cardiovascular medicine at the Brigham and Women's Hospital (BWH). From 1988 to 1993 Dr. Mendelsohn was a member of the faculty of the BWH Cardiology Division and an Assistant Professor of Medicine at Harvard Medical School. As a physician, scientist and international leader in molecular vascular biology, Dr. Mendelsohn has made major contributions to the field of molecul
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
2. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
3. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
4. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
6. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
7. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
8. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
9. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
10. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
11. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... DuPont Tate & Lyle Bio ... it has appointed Skidmore Sales & Distributing ... Essex Grain Products and Processor’s ... in the food and beverage markets. The ... mid-western states: Alabama, Arkansas, Connecticut, Delaware, Florida, ...
(Date:9/11/2014)... LONDON , Sept. 11, 2014 ... (CRT), the charity,s development and commercialisation arm, have reached ... biotechnology company in the emerging field of regenerative ... AST-VAC2 into clinical trials in subjects with non-small ... tenth treatment to enter Cancer Research UK,s Clinical ...
(Date:9/11/2014)... The Stem Cell Institute, located in ... umbilical cord stem cell therapy on Saturday, September 20, 2014 ... Resort from 1:00 pm to 4:00 pm. , Stem ... – “Umbilical Cord Stem Cell Clinical Trials for MS and ... founder of the Stem Cell Institute and Medistem Panama Inc. ...
(Date:9/10/2014)... Brunswick, New Jersey (PRWEB) September 11, 2014 ... will host its annual Innovations in Dermatological Sciences ... meeting will focus on how the university, industry ... dermatological research into clinical use. , This conference ... had experience with cross-sector collaboration, to share their ...
Breaking Biology Technology:DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 2DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 4Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 5Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 6Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 7Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 8Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 2Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 3Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 4Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... N.J., March 26 Vicus Therapeutics, LLC, ... Rao, Vice President Clinical Research and Development, ... 15th International,Molecular Medicine Tri-Conference on March 28st ... Convention Center in San Francisco. Dr. Rao ...
... JOLLA, Calif., March 26 TorreyPines,Therapeutics, Inc. (Nasdaq: ... and year ended December 31, 2007. For the full ... a net loss of $23.4 million.,Cash and cash equivalents ... made meaningful progress in our three clinical development programs,in ...
... 26 Pharsight,Corporation (Nasdaq: PHST ), a leading ... clinical drug,development announced today that it will be presenting ... Conference on April 2, 2008 at the Palms Las,Vegas. ... Vice President and CFO, will be presenting on April ...
Cached Biology Technology:TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 2TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 3TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 4TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 5TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 6TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 7Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference 2
(Date:9/11/2014)... DDT, American peregrine falcons ( Falco peregrines anatum ) ... stop rearing young birds in captivity and placing them ... models that year in ESA,s journal Ecological ... in California, with and without direct human intervention in ... would continue to recover without captive rearing, though the ...
(Date:9/11/2014)... 2014)Scientists today unveiled what appears to be the first ... New fossils of the massive Cretaceous-era predator reveal it ... years ago, providing the most compelling evidence to date ... an aquatic environment. The fossils also indicate that ... roam the Earth, measuring more than 9 feet longer ...
(Date:9/11/2014)... ago, a sudden, catastrophic event plunged much of the ... drought. This drastic climate changethe Younger Dryascoincided with the ... and the mastodon, and resulted in major declines in ... culture. , With limited evidence, several rival theories have ... such as a collapse of the North American ice ...
Breaking Biology News(10 mins):Volunteer 'eyes on the skies' track peregrine falcon recovery in California 2Volunteer 'eyes on the skies' track peregrine falcon recovery in California 3Volunteer 'eyes on the skies' track peregrine falcon recovery in California 4Volunteer 'eyes on the skies' track peregrine falcon recovery in California 5Scientists report first semiaquatic dinosaur, Spinosaurus 2Scientists report first semiaquatic dinosaur, Spinosaurus 3Scientists report first semiaquatic dinosaur, Spinosaurus 4Microscopic diamonds suggest cosmic impact responsible for major period of climate change 2
... A large collaborative study has added to the ... a person will be. The research, published by Cell ... of Human Genetics , identifies uncommon and previously unknown ... the genetic architecture of other complex traits. Although ...
... Most agricultural crops require large quantities of ... for growers is finding ways to balance the ... potentially harmful nitrates that can leach into ground ... "low-input" approaches is challenging researchers to identify genotypes ...
... traditionally relied heavily on hand thinning, a necessary but ... costs and a limited workforce, peach and other stone ... string thinners to minimize the need for hand thinning. ... when it was evaluated in four U.S. growing regions; ...
Cached Biology News:Large-scale analysis identifies new genetic alterations associated with height 2Improving nitrogen use efficiency lessens environmental impact 2Hybrid string blossom thinner tested in peach orchards 2
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Indoleamine 2,3-dioxygenase [IDO]...
Request Info...
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: